EUVIMEDEUVIMED entdecken
Crossref

Renal haemangioblastoma: a clinicopathologic and molecular characterization of 8 cases supporting the presence of recurrent MTOR pathway alterations

Maria Del Carmen Rodriguez Pena iD, Shujin He, Stephanie Siegmund iD, Michelle S Hirsch iD, Anjia Han iD, William J Anderson iD

Histopathology · 2025

DOI: 10.1111/his.15538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2025. Verfasst von Maria Del Carmen Rodriguez Pena und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Kidney Neoplasms, TOR Serine-Threonine Kinases, Hemangioblastoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Renal haemangioblastoma is a very rare mesenchymal neoplasm that remains incompletely characterized despite its inclusion in the WHO classification. In this study, we investigate the clinicopathologic and molecular features of renal haemangioblastoma. Methods and results The cohort comprised 8 patients (six male, two female) with a median age of 47 years (range: 29–63). No patients had a known history of a tumour predisposition syndrome. The tumours ranged in size from 1.3 to 8.0 cm (median: 4.0 cm). Histologically, the tumours were well circumscribed and composed of epithelioid/polygonal cells with clear‐to‐palely eosinophilic and often multivacuolated cytoplasm. In other areas, the tumour cells were more spindled. A prominent vascular pattern was frequently present. Two tumours were closely associated with renal cell carcinoma (RCC); the latter demonstrated features characteristic of RCC with fibromyomatous stroma (FMS). Targeted DNA sequencing was successfully performed on 7 tumours, revealing that most (5/7; 71%) harboured one or more alterations involving mTOR pathway genes. A total of 9 mTOR pathway alterations were identified, affecting MTOR ( n = 3), TSC1 ( n = 4), TSC2 ( n = 1) and PTEN ( n = 1). Immunohistochemistry for glycoprotein nonmetastatic B (GPNMB) was positive in 5/6 tumours assessed, including one tumour that lacked an identifiable mTOR pathway alteration by sequencing.

Conclusions

This study contributes further understanding to the pathogenesis of renal haemangioblastoma and supports that it exists on a spectrum with RCC with haemangioblastoma‐like features and RCC with FMS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsTOR Serine-Threonine KinasesHemangioblastomaHumansMaleFemaleMiddle AgedAdultSignal TransductionCarcinoma, Renal Cell

Stichwörter der Autor:innen

MTORPAX8RCChaemangioblastomainhibinkidneyrenal

Substanzen

TOR Serine-Threonine KinasesMTOR protein, human

Autor:innen und Institutionen

  • Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pathology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.

ORCID-Profile: Maria Del Carmen Rodriguez Pena, Stephanie Siegmund, Michelle S Hirsch, Anjia Han, William J Anderson

Zitieren

APA

Rodriguez Pena, M. D. C., He, S., Siegmund, S., Hirsch, M. S., Han, A., & Anderson, W. J. (2025). Renal haemangioblastoma: a clinicopathologic and molecular characterization of 8 cases supporting the presence of recurrent MTOR pathway alterations. Histopathology. https://doi.org/10.1111/his.15538

Vancouver

Rodriguez Pena MDC, He S, Siegmund S, Hirsch MS, Han A, Anderson WJ. Renal haemangioblastoma: a clinicopathologic and molecular characterization of 8 cases supporting the presence of recurrent MTOR pathway alterations. Histopathology. 2025. doi:10.1111/his.15538

BibTeX
@article{RodriguezPena2025,
  author = {Rodriguez Pena, Maria Del Carmen and He, Shujin and Siegmund, Stephanie and Hirsch, Michelle S and Han, Anjia and Anderson, William J},
  title = {Renal haemangioblastoma: a clinicopathologic and molecular characterization of 8 cases supporting the presence of recurrent MTOR pathway alterations},
  journal = {Histopathology},
  year = {2025},
  doi = {10.1111/his.15538}
}
Kostenlos starten →